Concurrent induction of CD4+ and CD8+ T cells during tumor growth with antitumor reactivity in adoptive immunotherapy

Journal of Immunotherapy

Volumn 20, Issue 2, 1997, Pages 138-145

  Arca, Marjorie J ^a   Krauss, John C ^b   Aruga, Atsushi ^a   Cameron, Mark J ^a   Chang, Alfred E ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adoptive immunotherapy; Cytokines; Gene therapy; Melanoma; T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; GENE THERAPY; IMMUNOREGULATION; LUNG METASTASIS; MELANOMA; MOUSE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR REGRESSION;

EID: 0031463663     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199703000-00006     Document Type: Article

References (32)

1. Miller AR, McBride WH, Hunt K, Economou JS. Cytokine-mediated gene therapy for cancer. Ann Surg Oncol 1994; 1:436-50.
2. Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MJ. In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol 1996;23:88-100.
3. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 1996;23:101-7.
4. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
5. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 1993;177:1127-34.
6. Stephenson KR, Perry-Lalley D, Griffith KD, Shu S, Chang AE. Development of antitumor reactivity in regional draining lymph nodes from tumor-immunized and tumor-bearing murine hosts. Surgery 1989;105:523-8.
7. Chang AE, Perry-Lalley DM, Shu S. Distinct immunologic specificity of tumor regression mediated by effector cells isolated from immunized and tumor-bearing mice. Cell Immunol 1989;120:419-29.
8. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially acitivated with anti-CD3 and Il-2. J Immunol 1991;147:729-37.
9. Yoshizawa H, Sakai K, Chang AE, Shu S. Activation of anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol 1991;134:473-9.
10. Yoshizawa H, Chang AE, Shu S. Cellular interaction in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res 1992;52:1129-36.
11. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and IL-2. J Clin Oncol (in press).
12. Weber JS, Jay G, Tanaka K, Rosenberg SA. Immunotherapy of a murine tumor with interleukin 2. J Exp Med 1987; 166:1716-33.
13. Geiger JD, Wagner PD, Cameron MJ, Shu S, Chang AE. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunother 1993;13:153-65.
14. Area MJ, Krauss JC, Aruga A, Camerona MJ, Shu S, Chang AE. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther 1996;3:39-47.
15. Area MJ, Krauss JC, Strome SE, Cameron MJ, Chang AE. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 1996;42:237-45.
16. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 1979;97:587-600.
17. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 1987;79:1067-75.
18. + tumor-infiltrating lymphocytes. J Exp Med 1991;173:647-58.
19. Massaro AF, Schoof DD, Rubinstein A, Zuber M, Leonard-Vidal FJ, Eberlein TJ. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes. Cancer Res 1990;50:2587-92.
20. - T cells in eradicating tumor cells in vivo. J Immunol 1984;133:1671-6.
21. - T cells: tumor eradication does not require participation of cytotoxic T cells. J Exp Med 1985;161:1122-34.
22. - T cells mediating delayed-type hypersensitivity response and in vivo protective immunity. Jpn J Cancer Res 1986;77:182-9.
23. Cheever MA, Greenberg PD, Irle C, et al. Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo. J Immunol 1984;132:2259-65.
24. Ettinghausen SE, Lipford EH, Mulé JJ, Rosenberg SA. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol 1985;135:1488-97.
25. + helper/killer T cells for the application to adoptive tumour immunotherapy. Br J Cancer 1992;66:20-6.
26. + helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. J Immunol 1992;148:285-91.
27. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
28. Cohen PJ, Cohen PA, Rosenberg SA, Katz SI, Mulé JJ. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur J Immunol 1994;24:315-9.
29. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 1996; 183:283-7.
30. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996;183:317-22.
31. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 179:1215-24.
32. Chang AE, Sondak VK, Bishop DK, Nickoloff BJ, Mulligan RC, Mulé JJ. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum Gene Ther 1996;7:773-92.